Brind.
  1. The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.
  2. Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.

EMA initially rejected Kisunla due to ARIA risks, affecting companies involved in Alzheimer's drug development.

2 reports, 2 independent Updated Jul 25
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

EMA initially rejected Kisunla due to ARIA risks, affecting companies involved in Alzheimer's drug development.

Who's involved

What this event is mainly about
Eli Lilly and CompanyBiogenEisai

Keep exploring

Part of

Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo. All 2 developments

Within The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.

The entities involved

Coverage

Newest first; wire copies grouped
  • BioPharma DiveIn reversal, European regulators take positive view on Lilly Alzheimer’s drug This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily Bi
  • Medical Device NetworkAccelerating innovation in early Alzheimer’s disease diagnosis Following a period of relative dormancy, research and development in the Alzheimer’s disease space is booming. And mounting attention, b